Diabetes drug metformin shows promise in reducing risk of cancer

An inexpensive drug that treats Type-2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher.

The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides for previously reported epidemiological surveys that long-term use of the drug for Type-2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.

The research appears in the current edition of .

"People with Type-2 diabetes are known to be at high risk for several diabetes-associated cancers, such as breast, liver and pancreatic cancers," said Trosko, a professor in the College of Human Medicine's Department of Pediatrics and Human Development. "While metformin has been shown in population studies to reduce the risk of these cancers, there was no evidence of how it worked."

For the study, Trosko and colleagues focused on the concept that cancers originate from adult human and that there are many natural and man-made chemicals that enhance the growth of .

Using culture dishes, they grew miniature human , or mammospheres, that activated a certain stem cell gene (Oct4A). Then the mammospheres were exposed to natural estrogen – a known growth factor and potential breast tumor promoter – and man-made chemicals that are known to promote tumors or disrupt the endocrine system.

The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit their stimulated growth in all cases.

"While future studies are needed to understand the exact mechanism by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," he said.

"Though we still do not know the exact molecular mechanism by which it works, metformin seems to dramatically affect how estrogen and endocrine-disrupting chemicals cause the pre-existing breast cancers to grow."

In addition, further research needs to be done with human cultures to see if metformin can reduce the risk of pancreatic and liver cancers in Type-2 diabetics as well, he said.

Related Stories

Penn researchers find diabetes drug kills some cancer cells

Aug 14, 2007

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53. Results from current studies in mice may result ...

Metformin may prevent lung cancer in smokers

Apr 19, 2010

Metformin, a mainstay of treatment for patients with type 2 diabetes, may soon play a role in lung cancer prevention if early laboratory research presented here at the AACR 101st Annual Meeting 2010 is confirmed in clinical ...

Recommended for you

New clinical trial launched for advance lung cancer

14 minutes ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

Physicians target the genes of lung, colon cancers

17 hours ago

(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.

User comments